SynthesisFrontiers in immunology2026

CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.

Chenhui Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.